NAGE
NASDAQ · Life Sciences Tools & Services
Niagen Bioscience Inc
$4.20
-0.27 (-6.04%)
Financial Highlights (FY 2026)
Revenue
113.99M
Net Income
15.31M
Gross Margin
64.3%
Profit Margin
13.4%
Rev Growth
+21.6%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 64.3% | 64.3% | 42.4% | 42.4% |
| Operating Margin | 12.6% | 11.3% | 16.1% | 15.1% |
| Profit Margin | 13.4% | 12.8% | 12.4% | 10.6% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 113.99M | 93.77M | 119.93M | 113.70M |
| Gross Profit | 73.27M | 60.28M | 50.83M | 48.19M |
| Operating Income | 14.34M | 10.62M | 19.31M | 17.15M |
| Net Income | 15.31M | 11.34M | 14.89M | 12.09M |
| Gross Margin | 64.3% | 64.3% | 42.4% | 42.4% |
| Operating Margin | 12.6% | 11.3% | 16.1% | 15.1% |
| Profit Margin | 13.4% | 12.8% | 12.4% | 10.6% |
| Rev Growth | +21.6% | +21.6% | +11.4% | +12.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 133.61M | 160.13M |
| Total Equity | — | — | 171.80M | 169.78M |
| D/E Ratio | — | — | 0.78 | 0.94 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 14.69M | 11.48M | 27.61M | 22.05M |
| Free Cash Flow | — | — | 17.96M | 17.42M |